作者: Agustin Avilés , Claudia Castañeda , Natividad Neri , Sergio Cleto , M Jesús Nambo
关键词: Dose-dense chemotherapy 、 Surgery 、 Regimen 、 Oncology 、 Stage (cooking) 、 Female patient 、 Complete response 、 Primary Breast Lymphoma 、 Toxicity 、 Internal medicine 、 Rituximab 、 Medicine
摘要: Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity dose dense regimen (CEOP-14) rituximab in 32 previously untreated female patients with PBL early stage. There was no difference complete response rate (87%), event free-survival (75%) overall survival (63%) compared historical patients.